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Abstract
Background: Despite its shortcomings, warfarin is still the most commonly prescribed anticoagulant to prevent
thromboembolism in children. In adults, numerous studies confirmed the robust relationship between warfarin
maintenance doses and single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9), vitamin K epoxide
reductase (VKORC1), and cytochrome P450 4F2 (CYP4F2). However, their effect in children still remains to be
determined. The primary objective of the present systematic review and meta-analysis is to assess the effect of
genotypes of CYP2C9, VKORC1, and CYP4F2 on warfarin maintenance dose in children.
Methods/design: A comprehensive literature review search using the OVID platform will be conducted by a
specialized librarian, without language restrictions (i.e., MEDLINE/EMBASE/Cochrane Central Register of Controlled
Trials), and all abstracts will be reviewed by two authors. Data abstraction from each eligible study will be extracted
individually by two authors (MT and TK), and disagreements will be resolved through discussion with a third person
(SI). Critical appraisal of the included analysis of the primary objective will follow the Newcastle–Ottawa Scale, in
addition to the Strengthening the Reporting of Genetic Association study (STREGA) statement, and data reporting
will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. For the
meta-analysis, the presence vs. absence of each genetic polymorphism will be pursued, respectively, using a
random effect model with effect size expressed as a mean difference plus 95 % confidence interval.
Discussion: Our study will provide a comprehensive systematic review and meta-analysis on the potential effects
of CYP2C9, VKORC1, or CYP4F2 on the warfarin maintenance dose in children, exploring the feasibility of the
development of pharmacogenetic-guided warfarin dosing algorithm for children on oral vitamin K antagonists.
Systematic review registration: The review has been registered with PROSPERO (registration number
CRD42015016172).
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Background
The diagnosis of thromboembolism (TE) has been in-
creasing in the world, and a considerable portion of those
events includes the pediatric population [1, 2]. Among the
anticoagulant agents used for the treatment of TE in
children, warfarin is the most commonly prescribed oral
anticoagulant for the treatment and prevention, including
primary anticoagulant prophylaxis for patient with heart
valve implants, single ventricle pathology which un-
derwent palliative surgery (e.g., post-Fontan operation),
coronary aneurysm of Kawasaki disease, and dilated
cardiomyopathy or for children with thrombotic events on
therapeutic anticoagulation [3–5]. However, one of the
challenges related to the use of warfarin pertains to its low
therapeutic index and the large inter-individual variability
in maintenance dose requirement [6]. For practical
purposes, an insufficient dose of warfarin would result in
failure to prevent thrombosis, while overdosing might
cause life-threatening hemorrhages [7]. Although the
variation in the initial and maintenance dose is known to
depend on body weight, age, and dietary vitamin K intake
as well as on environmental factors such as concomitant
medications, there is growing evidence for a strong
hereditary component [8–10].
Warfarin is a racemic mixture of R and S warfarin. The
average elimination half-life of S warfarin is 29 h, and that
of R warfarin is 45 h. The overall half-life is between 36
and 42 h. It is rapidly absorbed from the gut, and its peak
concentration is reached in 60 to 90 min [11]. Over the
last decade, a large body of evidence has accumulated
showing that polymorphism in three genes influence
warfarin dose. The three genes responsible for its metab-
olism and efficacy are as follows: cytochrome P450
2C9 (CYP2C9) is responsible for the metabolism of S
warfarin, vitamin K epoxide reductase complex subunit 1
(VKORC1) is the molecular target of warfarin, and cyto-
chrome P450 4F2 (CYP4F2) is the primary vitamin K1
oxidase in the liver. Based on these findings, several phar-
macogenetic approaches to guide optimal warfarin main-
tenance dose have been developed [12–19]. In 2007, the
US Food and Drug Administration modified the warfarin
label, stating that CYP2C9 and VKORC1 genotypes may
be useful to determine the optimal initial dose of warfarin
[20]. The label was updated in 2010 describing recom-
mendations for initial dosing ranges for patients with
different combinations of CYP2C9 and VKORC1 geno-
types. Subsequently, the Clinical Pharmacogenetics Imple-
mentation Consortium published the dosing guideline
[21] and also recommended the use of pharmacogenetic
test in determining initial warfarin doses in adults.
In children, although several pharmacogenetic studies ex-
ploring effects of genotypes on warfarin maintenance doses
have been reported [22–30], the effect of genotypes on war-
farin remains controversial. Given the variable findings of
the genotype–phenotype relationship in warfarin therapy in
children, critical analyses of the existing information would
be of utmost importance to provide clinicians an as-close-
as-possible evidence-based view of the literature, allowing
them to critically evaluate the need for this information to
be incorporated into the care of children being treated with
warfarin. The pursuit of such manuscript containing a sys-
tematic review and meta-analysis on this issue has moti-
vated us to plan for this study.
Our primary objective is to evaluate the effects of
CYP2C9, VKORC1, and CYP4F2 genotypes on war-
farin maintenance dose in children aged less than
18 years of age.
Methods/design
We will conduct a systematic review and meta-analysis
following the principles of the Cochrane Handbook for
Systematic Reviews of Intervention [31] and report the
data following the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) statement
[32] or the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses for Children (PRISMA-C)
which will be published soon. This protocol follows the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses Protocol 2015 (PRISMA-P), which is
included as Additional file 1 [33].
Primary outcome
The patient, intervention, comparator, outcome (PICO)
question formulated for this study will be as follows: In
children aged less than 18 years of age (P), do the
CYP2C9, VKORC1, and CYP4F2 genetic polymorphism
(I) compared with the CYP2C9, VKORC1, and CYP4F2
genetic wild type (C) impact on the variability of main-
tenance dose of patient receiving warfarin (O)?
The detail of the outcome is as follows:
1. Mean difference of warfarin maintenance dose between
CYP2C9 variant type (CYP2C9 *1/*2, CYP2C9 *1/*3,
CYP2C9 *2/*2, CYP2C9 *2/*3, or CYP2C9 *3/*3) and
wild type (CYP2C9 *1/*1) in children
2. Mean difference of warfarin maintenance dose
between VKORC1 variant type (VKORC1-1639GA,
VKORC-1639AA, VKORC1-1173CT, or VKORC1-
1173CT) and VKORC wild type (VKORC1-1639GG
or VKORC1-1173TT) in children
3. Mean difference of warfarin maintenance dose
between CYP4F2 variant type (CYP4F2-CT or
CYP4F2-TT) to that in the CYP4F2 wild type
(CYP4F2-CC) in children
We will combine the data regarding haplotypes of
VKORC1-1173C>T and VKORC1-1639G>A because these
two SNPs have a strong linkage disequilibrium [34]. The
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unit of mean difference of warfarin maintenance dose will
be expressed as milligrams per kilogram per day. When
warfarin maintenance dose, which is standardized to
milligrams per kilogram per day, is not applicable, we will
use standardized mean differences with 95 % confidence
interval (CI) for synthesis. Also, we will conduct subgroup
analysis according to the literature using milligrams
per kilogram per day as the outcome measure.
Search strategy and sources
A comprehensive literature review search using the
OVID platform will be conducted by a specialized librar-
ian, including MEDLINE, EMBASE, Cochrane Central
Register of Controlled Trial libraries, as well as gray
literature. We will identify relevant studies in any
language using medical subject headings (MeSH terms)
and text words related to “warfarin” AND “target SNPs”
AND “children.” Details of the search strategy are
provided in Additional file 2. An age filter (all children,
0 to 18 years) will be used in the MEDLINE and
EMBASE plus EMBASE classics search. We will also in-
clude studies published only as abstract or conference
reports. Additionally, we will hand-search the reference
lists of each eligible study included in the present and
previous systematic reviews to identify additional eligible
articles. In addition, the International Clinical Trials
Registry Platform Search Portal and ClinicalTrials.gov
will be searched for ongoing or recently completed trials
and the international prospective register of systematic
reviews (PROSPERO) will be searched for ongoing or re-
cently completed systematic reviews. As relevant studies
are identified, reviewers will check for additional rele-
vant cited and citing articles. The principal investigators
of studies will be contacted to clarify study eligibility if
required. Primary authors will also be contacted to as-
certain missing or unpublished data and their knowledge
of any other studies not retrieved by our primary search.
Our systematic review protocol was registered with the
PROSPERO on 27 February 2015 (registration number:
CRD42015016172). If this protocol needs any amend-
ments, we will provide the date of each amendment,
describe the change, and give the rationale, accordingly.
Changes will not be incorporated into the protocol.
Eligibility criteria
This review will focus on the potential association between
warfarin maintenance dose and genotypes of CYP2C9,
VKORC1, or CYP4F2 in children aged less than 18 years
old. We will define warfarin maintenance dose as the dose
to achieve three consecutive international normalized ratio
(INR) measurements within a therapeutic range over a
minimum of 4 weeks. We will include original studies
which meet the following criteria: (1) observational (cohort
or cross-sectional) studies or randomized controlled trials
in warfarin-treated pediatric patients; (2) genotypes of
CYP2C9, VKORC1, or CYP4F2 were reported; (3) children
receiving warfarin for at least 1 month; and (4) mainten-
ance doses of warfarin are presented according to each
genotype. There were no restrictions in the inclusion cri-
teria regarding patient demographic information including
body weight, height, use of concurrent drugs, indication
for warfarin use, and target INR ranges. We will exclude
case–control studies, case reports, case series, reviews,
editorials, news, and original studies which did not report
the outcome of interest in both the children and adults.
Duplicated studies will be also excluded. Pharmacogenetic
studies involving only adult population aged 18 or older
will be excluded. When a study involves both adult and
pediatric patients, we will exclude the study if the mean or
median age of the study population exceeded 18 years old
and subgroup analysis regarding children is unavailable.
Data collection and analysis
Study selection
Two reviewers (MT and TK) will independently screen
titles and abstracts of all the retrieved bibliographic
records. The inclusion and exclusion criteria will be used
for each screening step. If no abstract is available, the full
text will be obtained unless the article can be confidently
excluded by its title alone. If there is any doubt whether a
study should be excluded, the study will proceed to the
full-text screen to reduce the likelihood of incorrectly
excluding relevant studies. Full text of potentially eligible
studies will be independently retrieved by the two
reviewers. Disagreements at these screening levels (title/
abstract and full text) will be resolved through discussion
or adjudication of a third reviewer (SI).
Data extraction
After determination of the initial study, eligibility informa-
tion will be extracted for each study pertaining to study
identification (first author, year of publication, and country
where patients’ recruitment took place), study design,
patient population (number of enrolled patients, age,
gender, predominant ethnicity, concomitant drug use, diet,
indication for warfarin treatment, target INR range), and
primary outcome measurement (allele frequencies and
warfarin maintenance dose for each genotype of CYP2C9,
VKORC1, or CYP4F2). A list of the eligibility information
is presented in Additional file 3. In the case of duplicated
studies, we will use the study which had the largest num-
ber of patients. We will contact the original authors for
missing data if necessary. In order to standardize the unit
of warfarin dose to milligrams per kilogram per day, we
will also contact the original authors to obtain the data.
The two reviewers will independently extract data of all
eligible studies and summarize. The disagreement be-
tween the reviewers will be resolved by discussion. To
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ensure consistency across reviewers, we will conduct
pre-training of data extraction before starting the review.
Data management
Endnote X7 software will be used to upload literature
search results and de-duplicated by information regarding
author, year of publication, title, and reference type. The
Drop Box software, an Internet-based software program
that facilitates collaboration among reviewers during the
study selection process, will be used to store the literature
search results and PDF files of retrieved paper. The
uploaded data will be used only for the purposes stated in
this study and will not be forwarded to third parties.
Assessing a risk of bias of individual studies
Two reviewers will independently assess the risk of bias
of all eligible studies in accordance with the Newcastle–
Ottawa Scale (NOS) [35]. In addition, the Strengthening
the Reporting of Genetic Association study (STREGA)
statement will also be utilized [36]. The STREGA state-
ment represents an extension of the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) [37] and advocates for transparency how a
study was done by assessing a 12-item checklist which
are important to consider in genetic association studies.
These will be undertaken by two separate reviewers.
Where there is disagreement, a third reviewer will be
used as an arbitrator.
Data synthesis and presentation
We will weigh the studies by using the inverse variance
method and express the effect of each genetic variant on
warfarin maintenance doses as mean differences of the
doses between the wild type and the respective variant
with 95 % CI. When warfarin maintenance dose, which
is standardized to milligrams per kilogram per day, is
not applicable, we will use the standardized mean differ-
ences with 95 % CI for synthesis. When only the median
and range are available after contacting primary authors,
an imputation method proposed by Hozo et al. [38] will
be utilized. Anticipating the heterogeneity between stud-
ies, we will combine the data using the DerSimonian and
Laird random effect model [39]. A two-sided P value less
than 0.05 indicates a nominally significant overall associ-
ation. All statistical analyses will be performed by using
the Review Manager version 5.3 (the Nordic Cochrane
Centre, Copenhagen, Denmark) or EZR (Saitama Medical
Center, Jichi Medical University, Saitama, Japan) [40]. If
quantitative synthesis is not appropriate, we will provide a
systematic narrative synthesis with information presented
in the text and tables to summarize and explain the
characteristics and findings of the included studies.
Heterogeneity measures
We will assess the magnitude of inconsistency in the study
results by the I2 statistic which expresses the heterogeneity
as the percentage of total variation. We will arbitrarily
define the three categories of heterogeneity as follows:
I2 <30 %, low; I2 30–70 %, moderate; and I2 >70 %, high. If
high levels of heterogeneity among the studies are
observed (I2 ≥ 50 %), the study design and characteristics
in the included studies will be analyzed. We will try to
explain the source of heterogeneity by subgroup analysis
or sensitivity analysis.
Publication bias
Publication bias will be assessed using linear regression
test of the funnel plot asymmetry. A P value less than 0.10
will be considered to have publication bias. If asymmetry
is suggested by a visual assessment, we will perform
exploratory analyses to investigate and adjust it (trim and
fill analysis).
Planned sensitivity and subgroup analysis
Subgroup analyses will be used to explore possible sources
of heterogeneity, based on the following: (1) patient char-
acteristic (age, predominant ethnicity, indication for war-
farin); (2) target INR (median target range <2.5 or ≥2.5);
and (3) literature using milligrams per kilogram per day as
the outcome measure. Sensitivity analyses will be per-
formed in order to explore the source of heterogeneity as
follows: (1) quality components (full-text publication vs.
abstracts) and (2) quality of studies by omitting studies
that are judged to have lower quality.
GRADE framework
The proposed review will use the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE)
guidelines to determine the quality and strength of rec-
ommendations [41]. Quality will be adjudicated as high
(further research is very unlikely to change our confidence
in the estimate of effect), moderate (further research is
likely to have an important impact on our confidence in the
estimate of effect and may change the estimate), low (fur-
ther research is very likely to have an important impact on
our confidence in the estimate of effect and is likely to
change the estimate), or very low (very uncertain about the
estimate of effect).
Discussion
We hope that our systematic review and meta-analysis will
appropriately evaluate the effects of CYP2C9, VKORC1,
and CYP4F2 on warfarin maintenance dose in children.
Even though some previously published studies explored
the effect of genotypes on warfarin maintenance dose, the
role of genotypes in pediatric patients remains controver-
sial. On the one hand, Biss et al. [23] reported that
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VKORC1 and CYP2C9 affected the maintenance dose in
120 pediatric patients receiving warfarin, in addition to
Shaw et al. [28], who has also reported that warfarin dose
variability was attributed to VKORC1 and CYP2C9 poly-
morphisms in 93 pediatric patients. Similarly, there were
some literatures reporting that VKORC1 polymorphism
had an effect on warfarin maintenance dose in small sam-
ple size [22, 25, 27, 29]. Conversely, Kamal El-Din et al.
[30] showed that age was the most significant determinant
of the warfarin dose and CYP2C9 and VKORC1 polymor-
phisms did not have a major impact on the warfarin dose
in 41 Egyptian pediatric patients. Nowak-Gottl et al. [22]
and Nguyen et al. [27] also reported CYP2C9 had no
significant effect on warfarin maintenance dose in 34
pediatric patients and 50 pediatric patients with heart
disease, respectively. In this circumstance, Zhang et al.
[42] conducted a meta-analysis and have reported that
VKORC1-1639 polymorphism had an effect on warfarin
dose in pediatric patients in 2015. However, they did not
follow the Cochrane Handbook for Systematic Reviews of
Intervention or the PRISMA guidelines considered the
current gold standard guideline in the systematic review
field. Their protocol of meta-analysis was not peer
reviewed. In addition, the patients in the two literatures
they selected may overlap and they did not include data of
some literature meeting the eligibility criteria in the meta-
analysis. To avoid these flaws, we will conduct the
systematic review and meta-analysis officially following to
the principle of the Cochrane Handbook for Systematic
Reviews of Intervention and PRISMA guideline. More-
over, we will to utilize the STREGA checklist in addition
to NOS to assess the quality of study. This approach
will enable us to check whether the eligible literature
includes the essential information related to genetic
association study.
This study will benefit clinician by providing a summary
of effect of polymorphism on warfarin maintenance dose.
The results may also have an impact on patient care
and facilitate the development of a pharmacogenetic-
guided warfarin dosing algorithm in children.
Additional files
Additional file 1: PRISMA-P checklist: recommended items to address in
a systematic review protocol. (DOC 80 kb)
Additional file 2: Search terms and strategies. The search strategy
utilized is outlined in more detail in the file. (DOCX 23 kb)
Additional file 3: A list of the eligibility information. (PDF 3601 kb)
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